Published on in Vol 7, No 4 (2018): April

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/9024, first published .
Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis

Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis

Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis

Journals

  1. Skiba M, Islam R, Bell R, Davis S. Hormonal contraceptive use in Australian women: Who is using what?. Australian and New Zealand Journal of Obstetrics and Gynaecology 2019;59(5):717 View
  2. Ovsyannikova T, Kulikov I. Hormonal contraception in women of reproductive age: endocrinological aspects. Gynecology 2019;21(1):65 View
  3. Landersoe S, Larsen E, Forman J, Birch Petersen K, Kroman M, Frederiksen H, Juul A, Nøhr B, Løssl K, Nielsen H, Nyboe Andersen A. Ovarian reserve markers and endocrine profile during oral contraception: Is there a link between the degree of ovarian suppression and AMH?. Gynecological Endocrinology 2020;36(12):1090 View
  4. Amiri M, Nahidi F, Yarandi R, Khalili D, Tohidi M, Tehrani F. Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. Health and Quality of Life Outcomes 2020;18(1) View
  5. Morgante G, Cappelli V, Troìa L, De Leo V. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. The European Journal of Contraception & Reproductive Health Care 2020;25(3):176 View
  6. Aversa A, La Vignera S, Rago R, Gambineri A, Nappi R, Calogero A, Ferlin A. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Frontiers in Endocrinology 2020;11 View
  7. Qu X, Donnelly R. Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. International Journal of Molecular Sciences 2020;21(21):8191 View
  8. Waiyaput W, Wattanakamolchai K, Tingthanatikul Y, Lertvikool S, Tantanavipas S, Dittharot K, Sroyraya M, Sophonsritsuk A. Effect of combined contraceptive pill on immune cell of ovarian endometriotic tissue. Journal of Ovarian Research 2021;14(1) View
  9. Useinova A, Egorova E, Yelisheva E, Beitullaev А, Koryanova K. The main directions and prospects in polycystic ovary syndrome treatment. Сибирский научный медицинский журнал 2021;41(6):18 View
  10. Deng T, Liao X, Zhu S. Recent Advances in Treatment of Recurrent Spontaneous Abortion. Obstetrical & Gynecological Survey 2022;77(6):355 View
  11. Jain U, chimrani J, Krishna K. “THE EFFECT OF CYPROTERONE ACETATE AND ETHINYLESTRADIOL COMBINATION ON HYPERANDROGENIC AND OTHER SYMPTOMS IN PCOS”. GLOBAL JOURNAL FOR RESEARCH ANALYSIS 2021:43 View
  12. Ahmad F, Ahmed A, Shakeel A, Hussain H, Raza S. The efficacy of Linum usitatissimum seeds to inhibit estrogen receptor as a natural therapy for PCOS: An in silico and in vitro analysis. Cell Biochemistry and Function 2024;42(1) View

Books/Policy Documents

  1. Campesi I, Franconi F. Principles of Gender-Specific Medicine. View
  2. Messini C, Anifandis G, Daponte A, Messinis I. Textbook of Contraception, Sexual and Reproductive Health. View
  3. Lambrinoudaki I, Armeni E. Early Vascular Aging (EVA). View